13 completed, 2 recruiting, 2 terminated, 1 unknown. 18 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 13, Recruiting 2, Terminated 2, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow mepolizumab: new trials by email Literature Review of mepolizumab trials Research Report on mepolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group - Coronary Artery Disease | Phase 2 | Recruiting | Xijing Hospital | 18 | 2024-10-16 | 2026-01-23 |
| A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） SHR-1703, Mepolizumab Injection - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 166 | 2023-11-16 | 2025-12-04 |
| Immunological Basis for Mepolizumab Activity in COPD Mepolizumab 100 MG - COPD | Phase 2 | Unknown | Temple University | 30 | 2023-04-01 | 2023-04-07 |
| Mepolizumab in Episodic Angioedema With Eosinophilia mepolizumab - Eosinophilia, Angioedema | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2021-01-14 | 2024-04-16 |
| Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Mepolizumab, Placebo - COPD, Eosinophilia | Phase 2 / Phase 3 | Completed | University of Leicester | 238 | 2020-09-07 | 2026-04-24 |
| Mepo for Eosinophilic Esophagitis (EoE) Study Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo - EoE, Eosinophilic Esophagitis | Phase 2 | Completed | University of North Carolina, Chapel Hill | 66 | 2019-03-20 | 2023-08-23 |
| A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children Mepolizumab, Placebo - Asthma | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 335 | 2017-11-07 | 2022-07-20 |
| Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis Mepolizumab 100 mg, Placebo matching mepolizumab - Dermatitis, Atopic | Phase 2 | Terminated | GlaxoSmithKline | 34 | 2017-03-21 | 2020-02-25 |
| Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children Mepolizumab - Asthma | Phase 2 | Completed | GlaxoSmithKline | 36 | 2015-08-25 | 2019-12-03 |
| Anti-IL-5 Therapy in Bullous Pemphigoid (BP) Mepolizumab (a-IL-5 antibody), Placebo - Pemphigoid, Bullous | Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 32 | 2013-02-13 | 2017-02-28 |
| Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils Mepolizumab - Asthma | Phase 2 | Completed | GlaxoSmithKline | 70 | 2011-02-01 | 2017-01-11 |
| Mepolizumab in Nasal Polyposis Mepolizumab, Placebo, Run In Medication - Nasal Polyps | Phase 2 | Completed | GlaxoSmithKline | 109 | 2009-05-12 | 2021-04-12 |
| Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome mepolizumab - Churg Strauss Syndrome | Phase 2 | Completed | University Hospital Schleswig-Holstein | 10 | 2008-07-01 | 2012-06-15 |
| Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Mepolizumab - Churg Strauss Syndrome | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 10 | 2007-09-01 | 2017-03-22 |
| Intravenous Mepolizumab In Children With Eosinophilic Esophagitis mepolizumab - Oesophagitis, Eosinophilic | Phase 2 | Completed | GlaxoSmithKline | 84 | 2006-09-11 | 2018-07-24 |
| An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients mepolizumab - Oesophagitis, Eosinophilic | Phase 2 | Completed | GlaxoSmithKline | 10 | 2005-12-01 | 2016-12-05 |
| The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563) SB-240563 (Mepolizumab) - Asthma | Phase 2 | Completed | St. Joseph's Healthcare Hamilton | 20 | 2005-01-01 | 2011-01-24 |
| Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Mepolizumab - Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 24 | 2001-12-01 | 2020-07-29 |
Asthma (4) · Churg-Strauss Syndrome (4) · Eosinophilia (2) · Eosinophilic Esophagitis (2) · Esophagitis (2) · Pulmonary Disease, Chronic Obstructive (2) · Angioedema (1) · Coronary Artery Disease (1) · Dermatitis, Atopic (1) · Eosinophilic enteropathy (1) · Hypereosinophilic Syndrome (1) · Inflammation (1) · Nasal Polyps (1) · Pemphigoid, Bullous (1) · Pulmonary Eosinophilia (1)
GlaxoSmithKline (6) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Brigham and Women's Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Insel Gruppe AG, University Hospital Bern (1) · St. Joseph's Healthcare Hamilton (1) · Temple University (1) · University Hospital Schleswig-Holstein (1) · University of Leicester (1) · University of North Carolina, Chapel Hill (1) · Xijing Hospital (1)
United States (9) · United Kingdom (4) · Canada (3) · China (2) · Germany (2) · Switzerland (2) · Australia (1) · Belgium (1) · Estonia (1) · France (1) · Japan (1) · Netherlands (1) · Poland (1)
Chao Gao, M.D., Ph.D. (1) · Christopher Brightling (1) · Dagmar Simon (1) · Daniel J Jackson, MD (1) · Evan S Dellon, MD, MPH (1) · Frederick E Hargreave, MD (1) · Ling Tao, M.D., Ph.D. (1) · Marc E. Rothenberg, MD (1) · Michael Wechsler, MD (1) · Neil Greening (1) · Paneez Khoury, M.D. (1) · Ping Zhu, M.D., Ph.D. (1) · Thomas Rogers, PhD (1) · William W Busse, MD (1)
PMID 19264687, PMID 19828470, PMID 20542323, PMID 33710614, PMID 35964610, PMID 37423717, PMID 37577798, PMID 37951310, PMID 40305842, PMID 40658400, PMID 40897727
2008 (1), 2014 (1), UM1AI114271 (1)